Oak Street Health Reports Full Year 2021 Results
Oak Street Health (NYSE: OSH) reported significant financial results for 2021, achieving $1.43 billion in revenue, a 62% year-over-year increase. The company expanded its footprint by opening 50 centers across 8 states. Despite the growth, Oak Street faced a net loss of $(414.6) million, compared to $(192.1) million in 2020. Looking ahead, Oak Street plans to open 40 new centers in 2022 and aims for profitability by 2025, maintaining a compounded revenue growth rate of over 40%.
- Achieved $1.43 billion in revenue, up 62% year-over-year.
- Opened 50 new centers in 8 states during 2021.
- Capitated revenue reached $1.40 billion, a 64% increase.
- Aimed for profitability by 2025 with strategic center openings.
- Reported a net loss of $(414.6) million in 2021, worsening from $(192.1) million in 2020.
- Adjusted EBITDA was $(228.9) million, increasing from $(92.6) million in the prior year.
“We reported a strong quarter with results favorable to the high end of guidance across metrics. These results were thanks to the hard work and dedication of our team allowing Oak Street to navigate through a challenging operating environment, including the Omicron Covid surge and the historically tight labor market,” said
Full Year 2021 Financial Highlights
-
Total revenue was
, up$1.43 billion 62% year over year. -
Capitated revenue totaled
, up$1.40 billion 64% year over year. -
The Company cared for approximately 114,500 risk-based patients, representing
75% of its total patients. -
Net loss was
1, compared to$(414.6) million in 2020.$(192.1) million -
Adjusted EBITDA2 was
, compared to$(228.9) million in 2020.$(92.6) million -
As of
December 31, 2021 , the Company operated 129 centers, compared to 79 centers as ofDecember 31, 2020 .
_________________
1 Includes stock based and unit-based compensation of
2 Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure and is reconciled to net loss as the most directly comparable GAAP measure as set forth in the accompanying “Adjusted EBITDA Reconciliation” section. We define Adjusted EBITDA as net loss, excluding other income (expense), taxes, depreciation and amortization, stock-based and unit-based compensation and transaction/ offering related costs.
Outlook for Fiscal Year 2022
|
|
Three Months Ending |
|
Twelve Months Ending |
||||||||||||
|
|
|
|
|
||||||||||||
|
|
Low |
|
High |
|
Low |
|
High |
||||||||
(dollars in millions) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Centers |
|
|
138 |
|
|
|
139 |
|
|
|
169 |
|
|
|
169 |
|
At-risk patients |
|
|
122,500 |
|
|
|
123,500 |
|
|
|
152,500 |
|
|
|
157,500 |
|
Revenue |
$ |
|
505.0 |
|
|
|
510.0 |
|
$ |
|
2,100.0 |
|
|
|
2,135.0 |
|
Adjusted EBITDA |
$ |
|
(50.0 |
) |
|
|
(45.0 |
) |
$ |
|
(325.0 |
) |
|
|
(290.0 |
) |
We have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because of the uncertainty around certain items that may impact net loss, including stock-based and unit-based compensation, that are not within our control or cannot be reasonably predicted. However, for 1st quarter and fiscal year 2022, depreciation and amortization is expected to be approximately
Webcast and Conference Call
The Company will conduct a conference call
About
Founded in 2012,
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for the fiscal year 2021. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance.
Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operation; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our
Condensed Consolidated Balance Sheets (in millions) |
||||||||
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash |
$ |
|
104.7 |
|
$ |
|
409.3 |
|
Restricted cash |
|
|
15.7 |
|
|
|
10.4 |
|
Other receivables, net |
|
|
3.1 |
|
|
|
7.6 |
|
Capitated accounts receivable |
|
|
559.4 |
|
|
|
248.9 |
|
Marketable debt securities |
|
|
671.1 |
|
|
|
- |
|
Prepaid expenses |
|
|
7.9 |
|
|
|
6.8 |
|
Other current assets |
|
|
6.1 |
|
|
|
4.2 |
|
Total current assets |
|
|
1,368.0 |
|
|
|
687.2 |
|
|
|
|
|
|
|
|
|
|
Long-term assets: |
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
144.8 |
|
|
|
78.8 |
|
Security deposits |
|
|
1.9 |
|
|
|
1.3 |
|
Operating lease right-of-use assets |
|
|
157.7 |
|
|
|
- |
|
|
|
|
152.9 |
|
|
|
9.6 |
|
Intangible assets, net |
|
|
10.8 |
|
|
|
3.0 |
|
Other long-term assets |
|
|
5.0 |
|
|
|
1.1 |
|
Total assets |
$ |
|
1,841.1 |
|
$ |
|
781.0 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
$ |
|
22.1 |
|
$ |
|
8.8 |
|
Accrued compensation and benefits |
|
|
41.7 |
|
|
|
32.0 |
|
Liability for unpaid claims |
|
|
556.3 |
|
|
|
262.1 |
|
Other liabilities |
|
|
44.0 |
|
|
|
12.6 |
|
Total current liabilities |
|
|
664.1 |
|
|
|
315.5 |
|
|
|
|
|
|
|
|
|
|
Long-term liabilities: |
|
|
|
|
|
|
|
|
Long-term operating lease liabilities |
|
|
164.2 |
|
|
|
- |
|
Deferred rent expense |
|
|
- |
|
|
|
13.5 |
|
Other long-term liabilities |
|
|
55.4 |
|
|
|
28.8 |
|
Long-term debt, net of current portion |
|
|
901.4 |
|
|
|
- |
|
Total liabilities |
|
|
1,785.1 |
|
|
|
357.8 |
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
0.2 |
|
|
|
0.2 |
|
Additional paid-in capital |
|
|
1,017.9 |
|
|
|
971.8 |
|
Accumulated other comprehensive income |
|
|
(1.4 |
) |
|
|
- |
|
Accumulated deficit |
|
|
(965.3 |
) |
|
|
(555.8 |
) |
Total stockholders' equity allocated to the Company |
|
|
51.4 |
|
|
|
416.2 |
|
Noncontrolling interests |
|
|
4.6 |
|
|
|
7.0 |
|
Total stockholders' equity |
|
|
56.0 |
|
|
|
423.2 |
|
Total liabilities, redeemable investor units and stockholders' equity |
$ |
|
1,841.1 |
|
$ |
|
781.0 |
|
Condensed Consolidated Statements of Operations (in millions, except per share data) |
||||||||||||||||
|
|
For the twelve-months ended |
|
For the three-months ended (unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capitated revenue |
$ |
|
1,397.0 |
|
$ |
|
851.3 |
|
$ |
|
382.4 |
|
$ |
|
234.9 |
|
Other revenue |
|
|
35.6 |
|
|
|
31.5 |
|
|
|
11.7 |
|
|
|
13.8 |
|
Total revenues |
|
|
1,432.6 |
|
|
|
882.8 |
|
|
|
394.1 |
|
|
|
248.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical claims expense |
|
|
1,109.0 |
|
|
|
617.8 |
|
|
|
318.1 |
|
|
|
175.5 |
|
Cost of care, excluding depreciation and amortization |
|
|
293.7 |
|
|
|
187.5 |
|
|
|
90.1 |
|
|
|
61.0 |
|
Sales and marketing |
|
|
119.4 |
|
|
|
64.2 |
|
|
|
38.9 |
|
|
|
26.8 |
|
Corporate, general and administrative expenses |
|
|
306.7 |
|
|
|
185.6 |
|
|
|
82.4 |
|
|
|
73.1 |
|
Depreciation and amortization |
|
|
17.8 |
|
|
|
11.2 |
|
|
|
6.1 |
|
|
|
3.1 |
|
Total operating expenses |
|
|
1,846.6 |
|
|
|
1,066.3 |
|
|
|
535.6 |
|
|
|
339.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(414.0 |
) |
|
|
(183.5 |
) |
|
|
(141.5 |
) |
|
|
(90.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income/(expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
(2.5 |
) |
|
|
(8.7 |
) |
|
|
(0.7 |
) |
|
|
0.1 |
|
Other |
|
|
- |
|
|
|
0.1 |
|
|
|
- |
|
|
|
(0.1 |
) |
Total other expense |
|
|
(2.5 |
) |
|
|
(8.6 |
) |
|
|
(0.7 |
) |
|
|
0.0 |
|
Income before income taxes and non-controlling interests |
$ |
|
(416.5 |
) |
$ |
|
(192.1 |
) |
$ |
|
(142.2 |
) |
$ |
|
(90.8 |
) |
Provision for income taxes |
|
|
(1.9 |
) |
|
|
- |
|
|
|
(1.9 |
) |
|
|
- |
|
Net loss |
|
|
(414.6 |
) |
|
|
(192.1 |
) |
|
|
(140.3 |
) |
|
|
(90.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to noncontrolling interests |
|
|
5.2 |
|
|
|
4.1 |
|
|
|
1.7 |
|
|
|
3.6 |
|
Net loss attributable to the Company |
$ |
|
(409.4 |
) |
$ |
|
(188.0 |
) |
$ |
|
(138.6 |
) |
$ |
|
(87.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Undeclared and deemed dividends |
$ |
|
- |
|
$ |
|
(27.2 |
) |
$ |
|
- |
|
$ |
|
- |
|
Net loss attributable to common stock/unitholders |
|
|
(409.4 |
) |
|
|
(215.2 |
) |
|
|
(138.6 |
) |
|
|
(87.2 |
) |
Weighted average common stock outstanding - basic and diluted1 |
|
|
222,553,237 |
|
|
|
218,825,324 |
|
|
|
224,394,837 |
|
|
|
219,003,572 |
|
Net loss per share – basic and diluted |
$ |
|
(1.84 |
) |
|
|
(0.55 |
) |
$ |
|
(0.62 |
) |
|
|
(0.40 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. Basic and diluted earnings per share of common stock is applicable only for periods after the Company's IPO that was completed on |
|
|||||||||||||||
Condensed Consolidated Statements of Cash Flows (in millions, unaudited) |
||||||||
|
|
Twelve-Months Ended |
||||||
|
|
|
|
|
||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
Net loss |
$ |
|
(414.6 |
) |
$ |
|
(192.1 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Income tax benefit |
|
|
(1.9 |
) |
|
|
- |
|
Amortization of discount on debt and related issuance costs |
|
|
3.5 |
|
|
|
4.4 |
|
Accretion of discounts and amortization of premiums on short-term marketable securities, net |
|
|
4.6 |
|
|
|
- |
|
Depreciation and amortization |
|
|
17.8 |
|
|
|
11.2 |
|
Non-cash operating lease costs |
|
|
15.5 |
|
|
|
- |
|
Stock and unit-based compensation, net of forfeitures |
|
|
161.4 |
|
|
|
77.4 |
|
Change in fair value of bifurcated derivative |
|
|
- |
|
|
|
0.2 |
|
Change in operating assets and liabilities, net of impact of acquisitions: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(304.7 |
) |
|
|
(88.3 |
) |
Other assets |
|
|
(3.0 |
) |
|
|
(1.6 |
) |
Accounts payable |
|
|
5.7 |
|
|
|
(3.3 |
) |
Accrued compensation and benefits |
|
|
9.7 |
|
|
|
3.4 |
|
Liability for unpaid claims |
|
|
294.2 |
|
|
|
91.5 |
|
Operating lease liabilities |
|
|
(12.2 |
) |
|
|
- |
|
Other current liabilities |
|
|
7.4 |
|
|
1.6 |
|
|
Other long-term liabilities |
|
|
19.4 |
|
|
|
17.8 |
|
Other |
|
|
- |
|
|
|
0.6 |
|
Net cash used in operating activities |
|
|
(197.2 |
) |
|
|
(77.2 |
) |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Proceeds from sales and maturities of marketable debt securities |
|
|
193.6 |
|
|
|
- |
|
Purchases of marketable debt securities |
|
|
(870.7 |
) |
|
|
- |
|
Purchase of promissory note |
|
|
- |
|
|
|
(0.8 |
) |
Investment in business |
|
|
(5.0 |
) |
|
|
- |
|
Purchase of business, net of cash acquired |
|
|
(124.0 |
) |
|
|
- |
|
Purchases of property and equipment |
|
|
(81.3 |
) |
|
|
(20.9 |
) |
Net cash used in investing activities |
|
|
(887.4 |
) |
|
|
(21.7 |
) |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from initial public offering |
|
|
- |
|
|
|
377.3 |
|
Payments of underwriting fees, net of discounts and offering costs |
|
|
- |
|
|
|
(26.1 |
) |
Principal payments on long-term debt |
|
|
- |
|
|
|
(80.0 |
) |
End of term charge and prepayments for debt paydown |
|
|
- |
|
|
|
(5.8 |
) |
Proceeds from borrowings on convertible senior notes, net |
|
|
897.9 |
|
|
|
- |
|
Purchase of capped calls |
|
|
(123.6 |
) |
|
|
- |
|
Proceeds from issuance of redeemable investor units |
|
|
- |
|
|
|
224.4 |
|
Capital contributions from non-controlling interests |
|
|
4.2 |
|
|
|
5.9 |
|
Capital distributions to non-controlling interests |
|
|
(1.5 |
) |
|
|
(0.1 |
) |
Tender Offer - common units |
|
|
- |
|
|
|
(19.4 |
) |
Proceeds from exercise of options |
|
|
5.3 |
|
|
|
0.1 |
|
Proceeds from issuance of common stock under the employee purchase plan |
|
|
3.0 |
|
|
|
- |
|
Net cash provided by financing activities |
|
|
785.3 |
|
|
|
476.3 |
|
|
|
|
|
|
|
|
|
|
Net change in cash, cash equivalents and restricted cash |
|
|
(299.3 |
) |
|
|
377.4 |
|
Cash, cash equivalents and restricted cash, beginning of period |
|
|
419.7 |
|
|
|
42.3 |
|
Cash, cash equivalents and restricted cash, end of period |
$ |
|
120.4 |
|
$ |
|
419.7 |
|
Non-GAAP Financial Measures
Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the
Patient Contribution Reconciliation
Patient Contribution is a non-GAAP financial measure that we define as capitated revenue less medical claims expense. The following is a reconciliation of our loss from operations, the most directly comparable GAAP financial measure, to Patient Contribution, for the three and twelve-months ended
|
|
For the three-months ended |
|
For the twelve-months ended |
||||||||||||
(dollars in millions) |
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Loss from operations |
$ |
|
(141.5 |
) |
$ |
|
(90.8 |
) |
$ |
|
(414.0 |
) |
$ |
|
(183.5 |
) |
Other revenue |
|
|
(11.7 |
) |
|
|
(13.8 |
) |
|
|
(35.6 |
) |
|
|
(31.5 |
) |
Cost of care, excluding depreciation and amortization |
|
|
90.1 |
|
|
|
61.0 |
|
|
|
293.7 |
|
|
|
187.5 |
|
Sales and marketing |
|
|
38.9 |
|
|
|
26.8 |
|
|
|
119.4 |
|
|
|
64.2 |
|
Corporate, general and administrative expenses |
|
|
82.4 |
|
|
|
73.1 |
|
|
|
306.7 |
|
|
|
185.6 |
|
Depreciation and amortization |
|
|
6.1 |
|
|
|
3.1 |
|
|
|
17.8 |
|
|
|
11.2 |
|
Patient contribution |
$ |
|
64.3 |
|
$ |
|
59.4 |
|
$ |
|
288.0 |
|
$ |
|
233.5 |
|
Platform Contribution Reconciliation
Platform Contribution is a non-GAAP financial measure that we define as total revenues less the sum of medical claims expense and cost of care, excluding depreciation and amortization. The following is a reconciliation of our loss from operations, the most directly comparable GAAP financial measure, to Platform Contribution, for the three and twelve-months ended
|
|
For the three-months ended |
|
For the twelve-months ended |
||||||||||||
(dollars in millions) |
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Loss from operations |
$ |
|
(141.5 |
) |
$ |
|
(90.8 |
) |
$ |
|
(414.0 |
) |
$ |
|
(183.5 |
) |
Depreciation and amortization |
|
|
6.1 |
|
|
|
3.1 |
|
|
|
17.8 |
|
|
|
11.2 |
|
Corporate, general and administrative |
|
|
82.4 |
|
|
|
73.1 |
|
|
|
306.7 |
|
|
|
185.6 |
|
Sales and marketing |
|
|
38.9 |
|
|
|
26.8 |
|
|
|
119.4 |
|
|
|
64.2 |
|
Stock and unit-based compensation* |
|
|
0.5 |
|
|
|
- |
|
|
|
1.6 |
|
|
|
- |
|
Platform contribution |
$ |
|
(13.6 |
) |
$ |
|
12.2 |
|
$ |
|
31.5 |
|
$ |
|
77.5 |
|
*Platform contribution was recast to exclude stock and unit-based compensation in 2021. There was no stock and unit-based compensation in 2020 to adjust. The recasted numbers for the quarters ended
Adjusted EBITDA Reconciliation
Adjusted EBITDA is a non-GAAP financial measure that we calculate as net loss adjusted to exclude (i) stock and unit-based compensation expense, (ii) depreciation and amortization, (iii) interest expense and other income, net, (iv) transaction and offering costs and (v) provision for income taxes. Our management team uses Adjusted EBITDA as a performance measure in order to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities. The following is a reconciliation of our net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA, for the three and twelve-months ended
|
|
For the three-months ended |
|
For the twelve-months ended |
||||||||||||
(dollars in millions) |
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Net loss |
$ |
|
(140.3 |
) |
$ |
|
(90.8 |
) |
$ |
|
(414.6 |
) |
$ |
|
(192.1 |
) |
Interest expense and other income |
|
|
0.7 |
|
|
|
(0.0 |
) |
|
|
2.5 |
|
|
|
8.6 |
|
Depreciation and amortization |
|
|
6.1 |
|
|
|
3.1 |
|
|
|
17.8 |
|
|
|
11.2 |
|
Stock and unit-based compensation |
|
|
39.5 |
|
|
|
43.0 |
|
|
|
161.4 |
|
|
|
78.6 |
|
Transaction/offering related costs |
|
|
2.3 |
|
|
|
1.1 |
|
|
|
5.9 |
|
|
|
1.1 |
|
Provision for income taxes |
|
|
(1.9 |
) |
|
|
- |
|
|
|
(1.9 |
) |
|
|
- |
|
Adjusted EBITDA |
$ |
|
(93.6 |
) |
$ |
|
(43.6 |
) |
$ |
|
(228.9 |
) |
$ |
|
(92.6 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005792/en/
Media:
Vice President of Public Relations
(330) 990-5026
Erica.Frank@oakstreethealth.com
Investors:
Head of Investor Relations
(773) 572-0254
sarah.cluck@oakstreethealth.com
Source:
FAQ
What were Oak Street Health's revenue figures for 2021?
How many centers did Oak Street Health open in 2021?
What is Oak Street Health's net loss for 2021?
What is Oak Street Health's revenue guidance for 2022?